Emerging research is highlighting new approaches that could make cholesterol treatment more convenient for some patients, potentially improving long-term management of cardiovascular disease. Recent studies have examined both a once-daily oral medication, enlicitide (formerly known as Lipfendra), and the twice-yearly injectable therapy inclisiran, with findings suggesting these treatments may help lower low-density lipoprotein (LDL), or "bad," cholesterol while offering alternatives to traditional daily statin therapy.
According to reports from Healthline and other medical news outlets, these therapies are designed to complement, not necessarily replace, existing cholesterol-lowering medications. Researchers and clinicians say expanding treatment options may help improve medication adherence, particularly for patients who struggle with taking daily medications or who require additional LDL cholesterol reduction to lower their cardiovascular risk.
New Therapies May Help Patients Stay Consistent With Cholesterol Treatment
Recent clinical studies have evaluated two newer approaches to lowering LDL cholesterol. One is enlicitide, an investigational once-daily oral PCSK9 inhibitor that has shown promising reductions in LDL cholesterol during clinical trials. The other is inclisiran, an approved small interfering RNA (siRNA) therapy that lowers LDL cholesterol by reducing production of the PCSK9 protein and is administered initially, again after three months, and then every six months thereafter.
Researchers believe these options may improve medication adherence by reducing barriers associated with long-term treatment. A once-daily oral therapy may appeal to patients who prefer pills over injections, while a twice-yearly maintenance injection may benefit individuals who have difficulty remembering daily medications.
Experts caution, however, that cholesterol treatment is not one-size-fits-all. Cardiovascular risk varies based on factors such as age, LDL cholesterol levels, diabetes, smoking status, family history, and previous cardiovascular events. Physicians consider these factors when recommending treatment plans, which may include lifestyle changes, statins, newer therapies, or a combination of medications.
As one cardiologist told Medical News Today, "The best cholesterol-lowering therapy is the one a patient can consistently take as prescribed." The growing number of treatment options may allow clinicians to better tailor therapy to individual needs.
How Lowering Cholesterol Helps Heart Health
High cholesterol, also known as hyperlipidemia, occurs when excessive levels of fats, including LDL cholesterol, circulate in the blood. According to the Mayo Clinic and Cleveland Clinic, elevated LDL cholesterol can gradually accumulate within artery walls, forming plaques that narrow blood vessels and increase the risk of heart attack, stroke, and other cardiovascular diseases.
Reducing LDL cholesterol is one of the most effective ways to lower cardiovascular risk. Lifestyle measures, including a heart-healthy diet, regular physical activity, maintaining a healthy weight, and avoiding tobacco, remain the foundation of treatment.
Medications such as statins continue to be the first-line therapy for many patients, while newer options like inclisiran and investigational oral PCSK9 inhibitors may provide additional LDL lowering for individuals who need it or cannot achieve treatment goals with standard therapy alone.
These newer therapies represent an expansion of the treatment landscape rather than a replacement for established medications. Experts emphasize that the most appropriate therapy depends on each patient's medical history, overall cardiovascular risk, and treatment response.
Taking Cholesterol Treatments Forward
Cardiovascular disease remains one of the leading causes of illness and death worldwide, making effective cholesterol management an important public health priority. While many cholesterol-lowering medications are highly effective, maintaining long-term adherence can be challenging, particularly for people taking multiple daily medications or those who experience treatment fatigue.
The development of additional treatment options, including investigational oral therapies and infrequently administered injections, may help address these challenges by giving physicians and patients greater flexibility when developing personalized treatment plans. Improved adherence may translate into better long-term LDL cholesterol control, which has been consistently associated with lower cardiovascular risk.
Although some of these therapies are still being evaluated and may not be appropriate for every patient, the latest research highlights continued progress in cholesterol management. As scientists develop more individualized treatment strategies, patients may have greater opportunities to choose therapies that fit their preferences, lifestyles, and cardiovascular risk profiles while supporting long-term heart health.
